Baumgartner JM, McKenzie S, Block S, Costantini TW, Lowy AM. Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. Journal of Surgical Research. 2018 Jan 1;221:183-9
Methodological Reviewer: Prosanto Chaudhury MD, MSc, FRCSC, FACS, Department of Surgery, McGill University
Clinical Reviewer: Chad Ball MD, MSc, FRCSC, FACS, Department of Surgery, University of Calgary
Clinical Reviewer: Sharon Weber MD, Department of Surgery, University of Wisconsin
Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA, for the Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: XIX. Applying Clinical Trial Results A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA.1999;282(8):771–77
Please read the above articles and be prepared to discuss the following:
- What is the clinical question being addressed?
- Is there a strong, independent, consistent association between the surrogate end point and the clinical end point?
- Is there evidence from other randomized controlled trials in other drug classes that improvement in the surrogate end point has consistently led to improvement in the target outcome?
- Is there evidence from the same randomized controlled trials in other classes that improvement in the surrogate end point has consistently led to improvement in the target outcome?
- How large, precise and lasting was the treatment effect?
- Are the likely treatment benefits worth the potential harms and costs?
- State the conclusion. Have the authors addressed the clinical question posed?
- Does the evidence support the conclusion?